RU2015143106A - Терапия злокачественных опухолей - Google Patents

Терапия злокачественных опухолей Download PDF

Info

Publication number
RU2015143106A
RU2015143106A RU2015143106A RU2015143106A RU2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A
Authority
RU
Russia
Prior art keywords
mycobacterium
malignant tumor
paragraphs
tumor
providing
Prior art date
Application number
RU2015143106A
Other languages
English (en)
Russian (ru)
Inventor
Торстен ХЭЙГМАНН
Original Assignee
Иммодулон Терапеутикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммодулон Терапеутикс filed Critical Иммодулон Терапеутикс
Publication of RU2015143106A publication Critical patent/RU2015143106A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
RU2015143106A 2013-05-09 2014-05-09 Терапия злокачественных опухолей RU2015143106A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1308325.8A GB201308325D0 (en) 2013-05-09 2013-05-09 Cancer Therapy
GB1308325.8 2013-05-09
PCT/GB2014/051421 WO2014181121A1 (en) 2013-05-09 2014-05-09 Cancer therapy

Publications (1)

Publication Number Publication Date
RU2015143106A true RU2015143106A (ru) 2017-06-15

Family

ID=48672024

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015143106A RU2015143106A (ru) 2013-05-09 2014-05-09 Терапия злокачественных опухолей

Country Status (18)

Country Link
US (1) US20160074494A1 (cg-RX-API-DMAC7.html)
EP (1) EP2994148B8 (cg-RX-API-DMAC7.html)
JP (1) JP2016520057A (cg-RX-API-DMAC7.html)
KR (1) KR20160022803A (cg-RX-API-DMAC7.html)
CN (1) CN105407901A (cg-RX-API-DMAC7.html)
AU (1) AU2014264434A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015025719A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907841A1 (cg-RX-API-DMAC7.html)
DK (1) DK2994148T3 (cg-RX-API-DMAC7.html)
ES (1) ES2618050T3 (cg-RX-API-DMAC7.html)
GB (1) GB201308325D0 (cg-RX-API-DMAC7.html)
HU (1) HUE031783T2 (cg-RX-API-DMAC7.html)
MX (1) MX2015014344A (cg-RX-API-DMAC7.html)
PL (1) PL2994148T3 (cg-RX-API-DMAC7.html)
RU (1) RU2015143106A (cg-RX-API-DMAC7.html)
SG (1) SG11201507847UA (cg-RX-API-DMAC7.html)
SI (1) SI2994148T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014181121A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
KR101832892B1 (ko) * 2015-08-24 2018-02-27 가톨릭대학교 산학협력단 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물
GB201601248D0 (en) * 2016-01-22 2016-03-09 Immodulon Therapeutics Ltd Cancer therapy
GB201608806D0 (en) * 2016-05-19 2016-07-06 Immodulon Therapeutics Ltd Method
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CN109329204B (zh) * 2018-10-12 2021-02-12 中国医学科学院北京协和医院 胰腺癌动物模型的构建方法
CN117286186A (zh) * 2022-06-16 2023-12-26 中国医学科学院北京协和医院 胰腺癌动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
WO2006109300A1 (en) 2005-04-14 2006-10-19 Hadasit Medical Research Services & Development Ltd. Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
BR112015025719A2 (pt) 2017-07-18
CA2907841A1 (en) 2014-11-13
EP2994148B1 (en) 2017-02-01
ES2618050T3 (es) 2017-06-20
JP2016520057A (ja) 2016-07-11
EP2994148B8 (en) 2017-08-30
MX2015014344A (es) 2016-06-21
CN105407901A (zh) 2016-03-16
SI2994148T1 (sl) 2017-07-31
PL2994148T3 (pl) 2017-07-31
WO2014181121A1 (en) 2014-11-13
DK2994148T3 (en) 2017-03-13
KR20160022803A (ko) 2016-03-02
US20160074494A1 (en) 2016-03-17
GB201308325D0 (en) 2013-06-19
HUE031783T2 (en) 2017-07-28
EP2994148A1 (en) 2016-03-16
SG11201507847UA (en) 2015-11-27
AU2014264434A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
JP2016520057A5 (cg-RX-API-DMAC7.html)
RU2016123370A (ru) Ингибитор контрольных точек и цельноклеточная микробактерия для использования при лечении онкологического заболевания
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
TW201613589A (en) Combination methods for treating cancers
HRP20191972T1 (hr) Pripravci i postupci za aktiviranje signalizacije ovisne o "stimulatoru gena interferona"
CN112888458A (zh) Cldn18的抗体和化疗药物的联合治疗
JP2016528162A5 (cg-RX-API-DMAC7.html)
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
RU2016102158A (ru) Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
PH12016502354A1 (en) Pharmaceutical composition
RU2017115771A (ru) 17a,21-диэфиры кортексолона для применения в лечении опухолей
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
RU2016147654A (ru) Соединения для лечения рака
RU2018102547A (ru) Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
IL276235B1 (en) Use of Minfrain to reduce tumor growth
PH12021552973A1 (en) Methods of treating urinary system cancers
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
MX2021015802A (es) Terapia de combinacion.
JP2024529457A5 (cg-RX-API-DMAC7.html)
JP2011500841A5 (cg-RX-API-DMAC7.html)
JP2013506626A5 (cg-RX-API-DMAC7.html)
JP2015516464A5 (cg-RX-API-DMAC7.html)
Dutcher High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard
Zhou et al. Advances in mechanisms and treatments of brain metastases
JP2020533368A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180314